drug resistant virus
Recently Published Documents


TOTAL DOCUMENTS

33
(FIVE YEARS 2)

H-INDEX

14
(FIVE YEARS 0)

Molecules ◽  
2021 ◽  
Vol 26 (4) ◽  
pp. 810
Author(s):  
Hang Yin ◽  
Ning Jiang ◽  
Wenhao Shi ◽  
Xiaojuan Chi ◽  
Sairu Liu ◽  
...  

Influenza virus is a highly contagious zoonotic respiratory disease that causes seasonal outbreaks each year and unpredictable pandemics occasionally with high morbidity and mortality rates, posing a great threat to public health worldwide. Besides the limited effect of vaccines, the problem is exacerbated by the lack of drugs with strong antiviral activity against all flu strains. Currently, there are two classes of antiviral drugs available that are chemosynthetic and approved against influenza A virus for prophylactic and therapeutic treatment, but the appearance of drug-resistant virus strains is a serious issue that strikes at the core of influenza control. There is therefore an urgent need to develop new antiviral drugs. Many reports have shown that the development of novel bioactive plant extracts and microbial extracts has significant advantages in influenza treatment. This paper comprehensively reviews the development and effects of chemosynthetic drugs, plant extracts, and microbial extracts with influenza antiviral activity, hoping to provide some references for novel antiviral drug design and promising alternative candidates for further anti-influenza drug development.


2019 ◽  
Vol 75 (1) ◽  
pp. 194-199
Author(s):  
Sara Modica ◽  
David Redi ◽  
Roberta Gagliardini ◽  
Emanuela Giombini ◽  
Antonia Bezenchek ◽  
...  

Abstract Background Antiretroviral drug resistance mutations remain a major cause of treatment failure. Objectives To evaluate the impact of NRTI resistance mutations on virological effectiveness of elvitegravir-containing regimens. Materials and methods We selected treatment-experienced HIV-1-infected patients starting elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF), with at least one protease/reverse transcriptase genotype available before switching and at least one HIV-1 RNA viral load (VL) measurement during follow-up. The primary endpoint was virological failure (VF), defined as one VL value of ≥1000 copies/mL or two consecutive VL values of >50 copies/mL. Results We included 264 ART regimens: 75.6% male, median (IQR) age 47 years (39–53), 7 years (3–16) of HIV infection, nadir CD4+ 247 cells/mm3 (105–361), 81.5% with VL ≤50 copies/mL and 11.7% with at least one NRTI mutation at baseline. Eleven (5.2%) VFs occurred in virologically suppressed patients versus eight (15.1%) in viraemic patients. The estimated probability of VF at 48 weeks with versus without any NRTI mutation was 7.4% (95% CI 2.3–12.5) versus 3.8% (2.1–5.5) in virologically suppressed patients and 66.7% (39.5–93.9) versus 11.2% (6.5–15.9) (P<0.001) in viraemic patients. The only predictor of VF was time on therapy (per 1 year more, adjusted HR 1.14, 95% CI 1.02–1.27, P=0.024) in viraemic patients. Conclusions A switch to E/C/F/TDF or E/C/F/TAF is safe for virologically suppressed patients without documented NRTI resistance, but not recommended in viraemic patients with a history of NRTI resistance. Although we did not detect a detrimental effect of past NRTI resistance in virologically suppressed patients, a fully active regimen remains preferred in this setting due to possible rebound of drug-resistant virus in the long term.


2018 ◽  
Vol 115 (40) ◽  
pp. 10136-10141 ◽  
Author(s):  
David A. Constant ◽  
Roberto Mateo ◽  
Claude M. Nagamine ◽  
Karla Kirkegaard

Many positive-strand RNA viruses translate their genomes as single polyproteins that are processed by host and viral proteinases to generate all viral protein products. Among these is dengue virus, which encodes the serine proteinase NS2B/3 responsible for seven different cleavages in the polyprotein. NS2B/3 has been the subject of many directed screens to find chemical inhibitors, of which the compound ARDP0006 is among the most effective at inhibiting viral growth. We show that at least three cleavages in the dengue polyprotein are exclusively intramolecular. By definition, such acis-acting defect cannot be rescued intrans. This creates the possibility that a drug-susceptible or inhibited proteinase can be genetically dominant, inhibiting the outgrowth of drug-resistant virus via precursor accumulation. Indeed, an NS3-G459L variant that is incapable of cleavage at the internal NS3 junction dominantly inhibited negative-strand RNA synthesis of wild-type virus present in the same cell. This internal NS3 cleavage site is the junction most inhibited by ARDP0006, making it likely that the accumulation of toxic precursors, not inhibition of proteolytic activity per se, explains the antiviral efficacy of this compound in restraining viral growth. We argue that intramolecularly cleaving proteinases are promising drug targets for viruses that encode polyproteins. The most effective inhibitors will specifically target cleavage sites required for processing precursors that exerttrans-dominant inhibition.


2017 ◽  
Vol 144 ◽  
pp. 196-204 ◽  
Author(s):  
Nitin Khandelwal ◽  
Yogesh Chander ◽  
Krishan Dutt Rawat ◽  
Thachamvally Riyesh ◽  
Chikkahonnaiah Nishanth ◽  
...  

2016 ◽  
Vol 21 (5) ◽  
Author(s):  
Manmohan Parida ◽  
Paban Kumar Dash ◽  
Jyoti S Kumar ◽  
Gaurav Joshi ◽  
Kundan Tandel ◽  
...  

To investigate the aetiology of the 2015 A(H1N1)pdm09 influenza outbreak in India, 1,083 nasopharyngeal swabs from suspect patients were screened for influenza A(H1N1)pdm09 in the state of Madhya Pradesh. Of 412 positive specimens, six were further characterised by phylogenetic analysis of haemagglutinin (HA) sequences revealing that they belonged to genogroup 6B. A new mutation (E164G) was observed in HA2 of two sequences. Neuraminidase genes in two of 12 isolates from fatal cases on prior oseltamivir treatment harboured the H275Y mutation.


2015 ◽  
Vol 21 (1) ◽  
pp. 37-44 ◽  
Author(s):  
Hideaki Kinugasa ◽  
Fusao Ikeda ◽  
Kouichi Takaguchi ◽  
Chizuru Mori ◽  
Takehiro Matsubara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document